Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.

@article{Eser2015SafetyAE,
  title={Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.},
  author={Alexander Eser and J -F Colombel and P. R. Rutgeerts and S{\'e}verine Vermeire and Harald Vogelsang and Martin Braddock and Tore Persson and Walter Reinisch},
  journal={Inflammatory bowel diseases},
  year={2015},
  volume={21 10},
  pages={
          2247-53
        }
}
BACKGROUND AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD). The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD. METHODS We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…